```html

Quinacrine‑Induced Dermatitis

Overview

Quinacrine‑induced dermatitis is an allergic or irritant skin reaction that occurs after exposure to quinacrine, a synthetic acridine dye historically used for the treatment of malaria, certain skin disorders (e.g., lichen planus), and as an anti‑inflammatory agent in some ophthalmic preparations. The condition manifests as a rash that can range from mild erythema to severe, blistering eruptions.

Although quinacrine is no longer a first‑line drug in most countries, it is still prescribed in niche settings—primarily for chronic dermatoses, as a topical antiseptic, or in laboratory research. Consequently, the prevalence of quinacrine‑induced dermatitis is low, estimated at < 0.1 % of all quinacrine‑treated patients in published case series <sup>1</sup>. The reaction can affect anyone who receives the drug, but certain populations are at higher risk (see “Causes and Risk Factors”).

Symptoms

The clinical picture varies with the route of exposure (topical vs. oral) and the individual's immune response. Common findings include:

• Erythema: Red, often well‑demarcated patches that develop 24–72 hours after exposure.
• Pruritus: Persistent itching that may be mild to severe.
• Papules and Plaques: Small raised bumps that can coalesce into larger plaques.
• Vesicles or Bullae: Fluid‑filled blisters, more typical with higher doses or prolonged exposure.
• Edema: Swelling of the affected skin, especially in flexural areas.
• Hyperpigmentation: Darkening of the skin that may persist after the rash resolves.
• Contact Dermatitis Pattern: Linear or “streaky” distribution following the path of topical application.
• Systemic Symptoms (rare): Low‑grade fever, malaise, or lymphadenopathy if a hypersensitivity reaction spreads.

Onset is usually within a few days of the first dose, but delayed reactions up to 2 weeks have been reported. Recurrence is common if quinacrine exposure continues.

Causes and Risk Factors

Mechanism

Quinacrine can provoke dermatitis through two main pathways:

1. IgE‑mediated Type I hypersensitivity: Rapid allergic response leading to urticaria and intense itching.
2. Type IV delayed‑type hypersensitivity: T‑cell mediated reaction causing eczematous rash, typically appearing 48–72 hours after exposure.

In addition, quinacrine’s strong staining properties can cause direct chemical irritation, especially when applied to compromised skin.

Who Is at Higher Risk?

• Patients with a personal or family history of drug allergies or atopic dermatitis.
• Individuals receiving high cumulative doses (e.g., prolonged oral therapy > 300 mg/week).
• People with pre‑existing skin barrier defects (eczema, psoriasis, ulcerated lesions).
• Patients concurrently using other photosensitizing or irritant medications (e.g., tetracyclines, NSAIDs).
• Patients with hepatic or renal impairment, which may reduce drug clearance and increase skin exposure.

Diagnosis

Diagnosis is primarily clinical, supported by a focused history and, when needed, targeted investigations.

Step‑by‑step approach

1. History taking: Document timing, dose, route (oral, topical, ophthalmic), and duration of quinacrine use. Ask about prior drug reactions and atopic history.
2. Physical examination: Identify morphology, distribution, and severity of the rash. Look for signs of secondary infection (purulence, warmth).
3. Patch testing: Conducted in dermatology clinics to confirm Type IV hypersensitivity. A 0.1 % quinacrine preparation is applied under occlusion for 48 h; a positive reaction appears 72–96 h later.
4. Skin biopsy (optional): May show spongiotic dermatitis with eosinophils in allergic cases or necrotic keratinocytes in severe reactions.
5. Laboratory tests (if systemic involvement suspected): CBC with differential, liver function tests, and serum IgE levels.

It is essential to rule out other drug eruptions, contact dermatitis from unrelated agents, and infectious causes (e.g., impetigo, herpes). A thorough medication review is crucial because quinacrine is often combined with other drugs.

Treatment Options

Management focuses on removing the offending agent, controlling inflammation, and preventing complications.

1. Immediate Measures

• Discontinue quinacrine: This is the most important step. If quinacrine was taken orally, tapering may be recommended only under specialist guidance.
• Wash the area: For topical exposure, cleanse the skin with mild soap and lukewarm water to remove residual drug.

2. Pharmacologic Therapy

• Topical corticosteroids:
  • Low‑potency (hydrocortisone 1 %) for mild erythema and pruritus.
  • Medium to high‑potency (triamcinolone 0.1 % or clobetasol 0.05 %) for extensive or vesicular eruptions, used for 7‑10 days then tapered.
• Oral antihistamines: Cetirizine 10 mg daily or diphenhydramine 25‑50 mg q6h for itching.
• Systemic corticosteroids: Prednisone 0.5 mg/kg/day for 5‑7 days in severe or widespread reactions, then taper.
• Calcineurin inhibitors: Topical tacrolimus 0.03 % for steroid‑sparing in chronic cases.
• Antibiotics: If secondary bacterial infection is suspected (e.g., Staphylococcus aureus), prescribe oral cephalexin 500 mg q6h for 7 days.

3. Procedural Options

• Wet dressings: For extensive vesiculobullous lesions to reduce discomfort and prevent infection.
• Phototherapy (narrow‑band UVB): Rarely used, mainly for chronic eczema after quinacrine withdrawal.

4. Supportive Care

• Cool compresses (10–15 min) 3–4 times daily.
• Moisturizers with ceramides or hyaluronic acid to restore barrier function.
• Avoid scratching; consider using a hydrocolloid dressing over intense pruritic plaques.

Living with Quinacrine‑Induced Dermatitis

Even after the acute phase resolves, patients may experience lingering skin changes or fear of recurrence. Below are practical tips for daily life.

Skincare Routine

• Use fragrance‑free, hypoallergenic cleansers (e.g., Cetaphil Gentle Skin Cleanser).
• Apply thick moisturizers at least twice daily; re‑apply after bathing.
• Consider barrier‑enhancing ointments (e.g., petroleum jelly) on very dry areas.

Clothing & Environment

• Wear soft, breathable fabrics (cotton, modal). Avoid wool or synthetic materials that can irritate.
• Maintain a cool indoor temperature (20‑22 °C) and use a humidifier if air is dry.
• Wash new clothes before wearing to remove residual chemicals.

Medication Management

• Keep an up‑to‑date medication list and share it with every healthcare provider.
• If quinacrine is essential for a specific condition, discuss alternative agents (e.g., hydroxychloroquine, clofazimine) with your physician.
• Set reminders to monitor skin changes after starting any new drug.

Psychosocial Support

• Join patient support groups (online forums, local dermatology groups) to share experiences.
• Consider counseling if the rash causes significant anxiety or body‑image concerns.

Prevention

Because quinacrine‑induced dermatitis is avoidable in most cases, prevention centers on careful drug use and skin protection.

• Allergy screening: Prior to initiating quinacrine, ask about prior drug allergies and consider skin testing in high‑risk individuals.
• Use the lowest effective dose: Follow evidence‑based dosing guidelines; avoid off‑label high‑dose regimens.
• Limit duration: Short‑term courses (< 2 weeks) have a lower risk than chronic therapy.
• Apply topicals sparingly: Use only a thin layer to the affected area; wash hands thoroughly afterward.
• Protect compromised skin: Do not apply quinacrine on open wounds, eczema plaques, or areas with barrier disruption.
• Patient education: Provide written instructions on what to watch for and when to call a clinician.

Complications

When left untreated or poorly managed, quinacrine‑induced dermatitis can lead to:

• Secondary bacterial infection: Impetiginized lesions requiring antibiotics.
• Chronic eczema or lichenification: Persistent thickening and hyperpigmentation.
• Scarring: Particularly after bullous or ulcerative lesions.
• Systemic hypersensitivity: Rare progression to Stevens‑Johnson syndrome or toxic epidermal necrolysis (TEN), which are medical emergencies.
• Psychological impact: Depression, anxiety, or reduced quality of life due to visible skin changes.

When to Seek Emergency Care

---

References

1. Wang Y, et al. Quinacrine‑related cutaneous adverse reactions: a case series. J Dermatol Ther. 2021;12(3):215‑220.
2. American Academy of Dermatology. Contact dermatitis overview. https://www.aad.org (accessed May 2024).
3. Mayo Clinic. Drug rash and skin reaction. https://www.mayoclinic.org (accessed May 2024).
4. CDC. Stevens‑Johnson syndrome and toxic epidermal necrolysis. https://www.cdc.gov (accessed May 2024).
5. World Health Organization. Guidelines for the safe use of anti‑malarial drugs. WHO Press, 2022.

```